机构名称：
¥ 1.0
In recent years, the overall five-year survival rate of cancers in China has improved to a certain extent, but there is still a lack of effective treatments for refractory tumors, such as advanced gastric cancer, pancreatic cancer, esophageal cancer, small cell lung cancer and triple-negative breast cancer as well as patients with drug resistance to platinum and PARP (poly ADP-ribose polymerase) inhibitors or immune checkpoint抑制剂等。迫切需要开发新型的抗肿瘤药物来满足这种临床需求。ATR激酶抑制剂有望为具有耐药性或难治性肿瘤患者带来新的治疗选择，目前在全球市场中尚无相同类型的产品。
中国生物制药有限
主要关键词
相关文件推荐
